EA200301098A1 - Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей - Google Patents

Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей

Info

Publication number
EA200301098A1
EA200301098A1 EA200301098A EA200301098A EA200301098A1 EA 200301098 A1 EA200301098 A1 EA 200301098A1 EA 200301098 A EA200301098 A EA 200301098A EA 200301098 A EA200301098 A EA 200301098A EA 200301098 A1 EA200301098 A1 EA 200301098A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
immunoglobulin
mouse
tumors
treatment
Prior art date
Application number
EA200301098A
Other languages
English (en)
Other versions
EA006310B1 (ru
Inventor
Кристина Мария Матео Де Акоста Дель Рио
Хосефа Ломбардеро Вальядарес
Лоурдес Татьяна Роке Наварро
Алехандро Лопес Рекена
Original Assignee
Сентро Де Инмунология Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентро Де Инмунология Молекулар filed Critical Сентро Де Инмунология Молекулар
Publication of EA200301098A1 publication Critical patent/EA200301098A1/ru
Publication of EA006310B1 publication Critical patent/EA006310B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение относится к получению модифицированных антител с использованием технологии рекомбинантных ДНК из мышиного моноклонального антитела P3 (MAb P3), продуцируемого гибридомной клеточной линией, депонированной в соответствии с Будапештским договором с номером доступа ECACC 94113026, и из антиидиотипического мышиного моноклонального антитела 1E10 (MAbai 1E10), продуцируемого гибридомной клеточной линией с депозитным номером ECACC 97112901, с целью получения моноклональных антител, которые сохраняют биологическкую функцию специфического связывания с антигеном исходных антител, но являются в то же самое время менее иммуногенными. Химерные антитела данного изобретения содержат вариабельные домены мышиного иммуноглобулина и константные области иммуноглобулина человека; и при гуманизации, наряду с содержанием константных областей иммуноглобулинов человека, они являются модифицированными в районе мышиных областей рамки считывания (FR) иммуноглобулина и, в частности, в тех зонах, которые могли бы находиться в антигенном сайте для Т-клеток, таким образом несколько положений этих FR являются также происходящими из иммуноглобулина человека. Эти антитела могут быть использованы в диагностике и терапии различных типов опухолей. Данное изобретение относится также к применению этих антител для терапевтических и диагностических целей.
EA200301098A 2001-04-06 2002-04-08 Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей EA006310B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000003 WO2002081496A2 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores

Publications (2)

Publication Number Publication Date
EA200301098A1 true EA200301098A1 (ru) 2004-04-29
EA006310B1 EA006310B1 (ru) 2005-10-27

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200301098A EA006310B1 (ru) 2001-04-06 2002-04-08 Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
EA200301097A EA006936B1 (ru) 2001-04-06 2002-04-08 Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200301097A EA006936B1 (ru) 2001-04-06 2002-04-08 Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды

Country Status (37)

Country Link
US (3) US20050069535A1 (ru)
EP (3) EP1798243B1 (ru)
JP (2) JP2004528033A (ru)
KR (3) KR100863509B1 (ru)
CN (3) CN101054417B (ru)
AR (2) AR033123A1 (ru)
AT (3) ATE406386T1 (ru)
AU (3) AU2002308348B2 (ru)
BG (2) BG66304B1 (ru)
BR (3) BR0208676B1 (ru)
CA (2) CA2443372C (ru)
CU (1) CU23007A1 (ru)
CZ (2) CZ304424B6 (ru)
DE (2) DE60228561D1 (ru)
DK (2) DK1384726T3 (ru)
EA (2) EA006310B1 (ru)
EC (2) ECSP034787A (ru)
ES (2) ES2312610T3 (ru)
HK (3) HK1066818A1 (ru)
HR (2) HRP20030805B1 (ru)
HU (2) HU228105B1 (ru)
IL (2) IL158246A0 (ru)
IS (2) IS6965A (ru)
MX (2) MXPA03008738A (ru)
MY (3) MY145703A (ru)
NO (2) NO331533B1 (ru)
NZ (2) NZ528598A (ru)
PE (1) PE20020972A1 (ru)
PL (2) PL208109B1 (ru)
PT (2) PT1384726E (ru)
SG (1) SG161737A1 (ru)
SI (2) SI1384726T1 (ru)
SK (2) SK287914B6 (ru)
UA (3) UA76745C2 (ru)
UY (2) UY27242A1 (ru)
WO (2) WO2002081496A2 (ru)
ZA (2) ZA200307585B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2006081826A2 (en) * 2005-02-04 2006-08-10 Survac Aps Survivin peptide vaccine
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
AU2006277785B2 (en) * 2005-08-11 2012-07-12 Matossian-Rogers Arpi TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
SI2407486T1 (en) * 2005-08-19 2018-04-30 Wyeth Llc Antagonist antibodies against GDF-8 and use in the treatment of ALS and other disorders associated with GDF-8
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
WO2009104649A1 (ja) * 2008-02-22 2009-08-27 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
NZ594985A (en) * 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
CA2757382A1 (en) * 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
AU2012205663B2 (en) * 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
CU24070B1 (es) 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
AU2013276131B2 (en) 2012-06-15 2017-08-24 Pfizer Inc. Improved antagonist antibodies against GDF-8 and uses therefor
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
NZ721309A (en) 2013-12-17 2019-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
KR101966408B1 (ko) * 2014-04-10 2019-04-05 오비아이 파머 인코퍼레이티드 항체，약학적 조성물 및 이의 용도
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
ES2957567T3 (es) 2015-06-16 2024-01-22 Hoffmann La Roche Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
KR102461228B1 (ko) 2016-11-30 2022-10-31 온코메드 파마슈티칼스, 인크. Tigit-결합제를 포함하는 암 치료 방법
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
ECSP034787A (es) 2004-01-28
AR033122A1 (es) 2003-12-03
DK1384726T3 (da) 2008-12-15
EP1411064B1 (en) 2007-11-14
MY137078A (en) 2008-12-31
DE60223547D1 (de) 2007-12-27
HRP20030805A2 (en) 2005-08-31
US8758753B2 (en) 2014-06-24
HK1066818A1 (ru) 2005-04-01
ES2312610T3 (es) 2009-03-01
HRP20030806B1 (en) 2011-11-30
ATE477279T1 (de) 2010-08-15
HUP0401355A2 (hu) 2004-10-28
UA75393C2 (en) 2006-04-17
HUP0401695A2 (en) 2006-08-28
EA006310B1 (ru) 2005-10-27
CN100349920C (zh) 2007-11-21
IS6965A (is) 2003-09-23
PT1411064E (pt) 2008-02-12
NO331533B1 (no) 2012-01-23
SI1411064T1 (sl) 2008-04-30
CZ20032641A3 (cs) 2004-07-14
CN1535282A (zh) 2004-10-06
IL158246A0 (en) 2004-05-12
UY27243A1 (es) 2002-09-30
NO20034437L (no) 2003-12-02
AU2002308347B2 (en) 2006-09-14
WO2002081661A3 (es) 2003-01-03
WO2002081496A3 (es) 2004-02-19
EP1798243B1 (en) 2010-08-11
NO20034437D0 (no) 2003-10-03
ATE378356T1 (de) 2007-11-15
CZ296276B6 (cs) 2006-02-15
BG108228A (bg) 2005-04-30
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
SK287783B6 (sk) 2011-09-05
HRP20030806A2 (en) 2005-08-31
PL371770A1 (en) 2005-06-27
EA200301097A1 (ru) 2004-02-26
BG108227A (bg) 2005-04-30
SK12262003A3 (sk) 2004-08-03
UA76745C2 (ru) 2006-09-15
CA2441845C (en) 2011-06-07
HU228105B1 (en) 2012-11-28
EP1798243A2 (en) 2007-06-20
AR033123A1 (es) 2003-12-03
EP1384726A2 (en) 2004-01-28
IS2701B (is) 2010-11-15
US20100297008A1 (en) 2010-11-25
CA2443372C (en) 2013-05-28
BR0208676A (pt) 2008-04-08
NZ528598A (en) 2005-03-24
HUP0401355A3 (en) 2012-05-29
BG66293B1 (en) 2013-02-28
EA006936B1 (ru) 2006-06-30
CN101054417B (zh) 2012-07-11
PT1384726E (pt) 2008-12-05
MY145703A (en) 2012-03-30
CN1319991C (zh) 2007-06-06
DE60223547T2 (de) 2008-09-18
CA2441845A1 (en) 2002-10-17
US20040253233A1 (en) 2004-12-16
KR20080080680A (ko) 2008-09-04
BG66304B1 (bg) 2013-03-29
SK12162003A3 (sk) 2004-05-04
AU2007231687B2 (en) 2010-09-30
ZA200307679B (en) 2005-03-30
JP2004525953A (ja) 2004-08-26
CU23007A1 (es) 2004-12-17
DE60228561D1 (de) 2008-10-09
HU228106B1 (en) 2012-11-28
JP2004528033A (ja) 2004-09-16
HK1109160A1 (en) 2008-05-30
CN101054417A (zh) 2007-10-17
CZ20032668A3 (cs) 2004-07-14
KR100919617B1 (ko) 2009-09-29
AU2007231687A1 (en) 2007-11-22
CZ304424B6 (cs) 2014-04-30
KR20030092048A (ko) 2003-12-03
MY157372A (en) 2016-06-15
US20050069535A1 (en) 2005-03-31
SI1384726T1 (sl) 2009-04-30
AU2002308348B2 (en) 2007-11-22
JP4366080B2 (ja) 2009-11-18
MXPA03008738A (es) 2003-12-11
EP1798243A3 (en) 2007-10-17
KR100863509B1 (ko) 2008-10-15
EP1411064A2 (en) 2004-04-21
CA2443372A1 (en) 2002-10-17
HK1070080A1 (en) 2005-06-10
BR0208676B1 (pt) 2017-11-14
UY27242A1 (es) 2002-07-31
PE20020972A1 (es) 2003-01-02
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
UA86768C2 (ru) 2009-05-25
BRPI0208675B1 (pt) 2018-03-13
NZ528599A (en) 2005-03-24
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
NO20034436L (no) 2003-12-02
CN1507452A (zh) 2004-06-23
BR0208675A (pt) 2004-08-03
SG161737A1 (en) 2010-06-29
IL158246A (en) 2010-05-31
ATE406386T1 (de) 2008-09-15
WO2002081496A2 (es) 2002-10-17
DK1411064T3 (da) 2008-03-25
IS6964A (is) 2003-09-23
HRP20030805B1 (en) 2011-11-30
HUP0401695A3 (en) 2012-05-29
ZA200307585B (en) 2004-09-16
KR100946168B1 (ko) 2010-03-11
ECSP034788A (es) 2004-01-28
ES2296986T3 (es) 2008-05-01
EP1384726B1 (en) 2008-08-27
MXPA03008739A (es) 2003-12-11

Similar Documents

Publication Publication Date Title
EA200301098A1 (ru) Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
MX9201016A (es) Anticuerpos monoclonales humanizados y quimericos
RU96115107A (ru) "очеловеченные" антитела и их использование
ATE137534T1 (de) Cdr-gepfropfte anti-cea-antikörper und ihre herstellung
NZ303375A (en) Monoclonal antibodies specific for different epitopes of human gp39 and diagnostic and therapeutic methods using them
ATE236251T1 (de) Anti-menschliche milchfettglobule humanisierte antikörper und verfahren zu ihrer herstellung
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
ATE464906T1 (de) Cdr-ausgetauschte typ iii anti-cea humanisierte monoklonale mausantikörper
CA2012993A1 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
ATE370235T1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
EA200100782A1 (ru) Антитела и fv фрагменты, разпознающие антиген ior c2
Orlandi et al. Characterization of a mouse‐human chimeric antibody to a cancer‐associated antigen
CY1107163T1 (el) Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων
Presta Humanized Monoclonal Antibodies
ESHHAR GENETICALLY ENGINEERED THERAPEUTIC ANTIBODIES
Hashizume et al. Clinical applications of human monoclonal antibodies
RU96109830A (ru) Антиидиотипические антитела, которые индуцируют иммунный ответ против рецептора эпидермального фактора роста
TH54150A (th) แอนติบอดี และชิ้นส่วน FV ที่สามารถยึดเหนี่ยว ior C2 แอนติเจน
JPH0665099A (ja) エイズ関連医薬品組成物
TH54150B (th) แอนดิบอดี และชิ้นส่วน FV ที่รู้จัก ior C2 แอนดิเจน

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU